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Background: Cancer is the second leading cause of death worldwide and the
third in Iran. Among cancers, cervical cancer is the third leading cause of death in women.
Thus, recognizing the epidemiology and trends of cervical cancer can be effective for
planning and policy-making. This study aims to investigate the incidence and trends
of cervical cancer in Iran due to the few studies that have addressed this issue and the
unclear trend for cervical cancer in Iran.
Methods: This study re-analyzed existing data from the cancer data recording system
in Iran during years 2003 to 2009. We used available data from the National Cancer
Registry and Center for Disease Control of the Ministry of Health, Treatment and Medical
Education. Stata software (version 11) was used for data analysis and the significance
of the incidence trend diagram was derived with WINPEPI software.
Results: Assessment of the National Cancer Registry statistics from 2003 to 2009
showed an increased trend in cervical cancer from 2003 to 2008 and a decreased trend
from 2008 to 2009. During this period, there were 4273 cases of cervical cancer
registered. From these, 394 cases were registered in 2003 which peaked at 907 cases
in 2009. The registered cancer cases had an approximately 3-fold increase during this
period. Most provinces reported an increased trend of incidence in cervical cancer.
Conclusion: Based on the results of this study, the incidence of cervical cancer is
increasing in Iran, especially in the central regions of the country. Therefore, considering the
growing trend of cancer, we recommend early detection through screening programs, public
awareness, and public training programs that particularly target high risk populations.
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Introduction
Cancer is the second cause of mortality after
cardiovascular diseases in developed countries,
including the United States.1 Among cancers,
cervical cancer is the third most common tumor
in women of the United States.1 This disease is the
seventh most common cancer and the sixth leading
cause of cancer-related mortality in women and
the first or second most common cancer of the
female reproductive system in some parts of
Africa, India, Central and South America, and
South and South-East Asia. Worldwide, 500,000
patients develop this cancer and approximately
200,000 patients die from this cancer annually.1
According to the World Health Organization
(WHO), 85% of cervical cancer cases are from
developing countries.1 There is a considerable
difference in the incidence and mortality rates of
this disease between developed and developing
countries.2 The mean age of patients who suffer
from this cancer is 52.2 years, while the peak
age of incidence is between 50-55 years of age.3,4
Smoking, multiple sexual partners, infection with
human papilloma virus, and oral contraceptive
pills (OCPs) are possible risk factors for cervical
cancer.5 Invasive cervical cancer is considered a
preventable cancer due to the lengthy period
before invasion, availability of an appropriate
screening program, and treatment of early lesions.6
This cancer accounts for 1.6% of cancer-related
deaths in women and 15% of deaths due to
gynecological cancers. Although cervical cancer
has not been eradicated, there is a decline in
incidence of invasive cases. Earlier diagnosis of
cervical cancer cases has improved patient
survival.7 In a study by Madeleine et al., the
increased risk of this disease in OCP users
depended on the duration of OCP consumption.
There was a 5-fold increased risk with more than
12 years of OCP use.8 Foreign studies could not
indicate the disease status in Iran. Although the
cancer prevalence has appeared to be elevated in
Iran, no study has assessed the trend of this
important disease and changes in its incidence and
epidemiology in recent decades. Most available
studies were regional studies that have assessed
small sample sizes. Epidemiologic data is
necessary for successful planning. Therefore, this
study aims to assess the trends in epidemiology of
cervical cancer in Iran from 2003 to 2009.
Materials and Methods
We conducted this descriptive study using
available data from the National Cancer Registry
and Center for Disease Control (CDC) of the
Ministry of Health, Treatment and Medical
Education. After we received the data, CDC
controlled the data in terms of proper coding,
missing demographic information, and deletion of
the repeated cases. In this study, all cases,
registered since 2003 to 2009 in the whole country
as well as the statistics of cervical cancer in all
provinces have been studied. The direct incidence
reported was then standardized according to the
world health organization (WHO) standards. The
collected data was accordingly investigated for the
whole country based on the number of cases and
standardized incidence rates for provinces.
Extracted information for the entire country were
studied based on the number of cases and
standardized incidence rates for provinces. After
gathering information about the disease trend
during the study years, we determined the
frequency and distribution of cervical cancer in the
following regions:
Region 1: Tehran, Qazvin, Qom, Mazandaran,
Semnan, Golestan.
Region 2: Bushehr, Isfahan, Fars, Charmahal-
Bakhtiari, Hormozgan, Kohkiluye Boyer-Ahmad.
Region 3: Kurdistan, East Azerbayjan, West
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Figure 1. The trend in incidence of cervical cancer from 2003 to
2009 in Iran.
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Azerbayjan, Guilan, Zanjan, Ardebil.
Region 4: Kermanshah, Hamadan, Lorestan, Ilam,
Markazi, Khuzestan.
Region 5: Yazd, Sistan-Baluchestan, South
Khorasan, Razavi Khorasan, North Khorasan,
Kerman.
In order to evaluate the trends in incidence, we
used Stata software (Version 11).
Results
Assessment of the National Cancer Registry
statistics from 2003 to 2009 showed an increased
trend for cervical cancer from 2003 to 2008 and
a decreased trend from 2008 to 2009 (Figures
1,2). According to the statistics during this period,
4273 cases of cervical cancer were registered
among Iranian women. We observed the most
cases (907) in 2009, with the least in 2003 (394;
Table 1). Cancer Registry statistics indicated that
the highest incidence rate was 2.61 per 100,000
women in 2009; the least was 1.64 per 100,000
women in 2003. Table 2 shows the standardized
incidence of cervical cancer during 2003-2009
among women from the 30 provinces according
to the Cancer Registry statistics. Yazd Province
had the highest incidence at 14.7 per 100,000
persons in 2009. Charmahal-Bakhtiari, Sistan-
Baluchestan, and Kohkiluyeh Boyer-Ahmad in
2003; Sistan-Baluchestan and Ilam in 2004; South
Khorasan in 2005; Ilam in 2008; and Kohkiluyeh
Boyer-Ahmad in 2009 had no reports of cervical
cancer in these provinces during the mentioned
years (Table 2). The statistics showed that the
central provinces had the highest incidence of
cervical cancer with an increased trend in these
provinces. The lowest incidence was reported in
the southern areas of the country. In this study, we
evaluated and compared the age-standardized
incidence rate (ASR) of cervical cancer in five
regions of the country (Figures 3, 4). The ASR for
cervical cancer in all regions of the country
increased, with the exception of the third
(Kurdistan, East Azerbayjan, West Azerbayjan,
Guilan, Zanjan, Ardebil) region which showed a
decrease. 
Discussion
Cervical cancer is one of the most common
cancers among women in developing countries
that has a worldwide prevalence.4 The ASR for all
cancers in Iran showed that the ASR for cervical
cancer increased to a maximum age of 80-84
years, with a decrease after the age of 85. The
cause for this decrease can be due to lack of
patients’ referral to diagnostic centers, lack of
access of the elderly to diagnostic facilities, or lack
of performing diagnostic tests by doctors at these
ages. According to the studies conducted in Iran,
cervical cancer includes 0.3% of all cancers in
women. Cervical cancer is a common invasive
cancer with variable rates of incidence and
prevalence throughout different regions of the
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Figure 2. Significance of the variance trend for cervical cancer in
Iran. [chi-sq = 0.07 (DF: 1) ; P=0.001]
Table 1. The incidence of cervical cancer in Iran based on the Cancer Registry Center statistics.
Statistics of the Age-standardized rate (ASR) Frequency (%) Number of cases
Cancer Registry Center
2003 1.64 2.34 394
2004 1.9 2.3 466
2005 1.86 1.91 469
2006 2.12 2.04 530
2007 2.47 2.19 600
2008 2.61 2.68 907
2009 2.17 2.8 907
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world.4, 5 In developing countries, cervical cancer
is considered the most common cancer among
women after breast cancer. In Asia, the lowest and
highest ASR of cervical cancer are present in
China with 3.2 per 100,000 women and Thailand
at 23.8 per 100,000 women.9,10 This rate is high
in many provinces in Iran. In Europe, the lowest
ASR for cervical cancer is seen in Albany
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Figure 3. Trend of the age-standardized rate (ASR) for cervical
cancer in five regions of Iran (2003-2009).
Figure 4. Average age-standardized rate (ASR) for cervical cancer
in five regions of Iran (2003-2009).
Table 2. The standardized incidence for cervical cancer in Iranian provinces (2003 to 2009).
Province 2003 2004 2005 2006 2007 2008 2009
Female Female Female Female Female Female Female 
East Azerbayjan 0.39 0.90 0.31 0.61 2.07 4.48 4.16
West Azerbayjan 0.72 1.78 1.98 0.73 0.97 2.59 2.54
Ardebil 0.21 2.50 2.08 2.12 1.38 1.63 1.46
Isfahan 0.92 2.64 2.78 2.84 1.28 5.59 5.99
Ilam 1.61 0.00 0.64 2.50 2.08 0.00 3.40
Bushehr 0.56 1.79 3.30 1.97 1.49 1.20 2.37
Tehran 4.24 2.56 3.02 1.95 2.72 6.72 5.84
Charmahal-Bakhtiari 0.00 1.47 1.86 1.23 1.84 0.74 1.23
South Khorasan 1.32 0.00 1.50 1.13 1.18 2.36 1.79
Razavi Khorasan 1.42 3.66 3.33 3.02 2.27
North Khorasan 0.85 0.90 3.18 0.42 0.75
Khuzestan 1.75 1.72 2.34 2.28 2.43 4.48 3.69
Zanjan 1.25 0.98 0.61 1.44 0.37 1.45 1.34
Semnan 2.43 3.40 2.30 1.52 3.04 3.54 4.87
Sistan-Baluchestan 0.00 0.00 0.43 0.27 0.51 0.55 1.29
Fars 1.50 1.13 2.32 1.58 4.10 4.04 3.51
Qazvin 0.86 1.21 2.51 1.47 2.06 1.93 2.18
Qom 0.65 0.88 3.31 2.07 2.39 1.40 1.67
Golestan 2.54 1.90 1.35 2.58 2.59 2.07 1.69
Guilan 2.02 1.90 2.44 1.85 1.69 2.86 3.15
Lorestan 1.19 0.87 1.67 1.76 2.49 2.56 2.49
Mazandaran 1.09 2.11 1.61 1.54 1.87 3.50 3.88
Markazi 0.00 0.74 2.41 1.33 2.06 2.03 5.43
Hormozgan 0.46 0.91 0.91 1.96 2.76 2.02 1.34
Hamadan 0.78 1.22 1.52 1.30 083 2.22 3.09
Kurdistan 0.19 1.03 2.04 1.89 2.24 3.05 2.62
Kerman 0.31 1.02 0.47 1.91 1.14 3.16 3.73
Kermanshah 0.87 1.22 1.95 1.50 1.08 2.60 2.21
Kohkiluye Boyer-Ahmad 0.00 1.44 0.50 0.45 0.67 0.99 0.00
Yazd 2.67 2.45 2.27 1.15 2.04 4.68 7.14
Cervical Cancer Incidence in Iran
(Southeastern Europe), (12.7 cases per 100,000
women) and the highest in the UK (44.2 cases per
100,000 women).9,11 According to Mousavi et
al., Iran had an ASR during 2005-2006 of 1.9 per
100,000 women.12
Table 2 shows that in 2003 the highest
incidence of cervical cancer was in Tehran (4.24
per 100,000 women) and Yazd (2.67 per 100,000
women) during 2003. However, in 2003,
Charmahal-Bakhtiari, Kohkiluyeh Boyer-Ahmad,
and Sistan-Baluchestan provinces reported no
cases of cervical cancer. These provinces had the
lowest rates of this disease. In 2004, the highest
incidence was observed in Semnan at 4.3 per
100,000 persons. The lowest incidence was noted
in Sistan-Baluchestan and Ilam provinces, which
had no reported cases of cervical cancer. These
findings supported the results of the above-
mentioned study. The results of a study by Smita
Asthana et al. in India during 2008 showed that
the incidence rate of cervical cancer had an
increased trend from 2004 to 2008, which was
consistent with the results of the present study.
This has taken into consideration the dramatic
increase of cervical cancer in less developed
countries.2, 13-15 In 2006, South Khorasan (3.66 per
100,000 persons) and Sistan-Baluchestan (0.27 per
100,000 persons) had the lowest incidence of this
cancer. In 2007, Fars province had the highest rate
of cervical cancer (4.10 per 100,000 persons),
whereas Zanjan province had the lowest incidence
rate at 0.37 per 100,000 persons. An assessment
of the province incidence rates indicated an
increasing trend in most areas of the country.
This finding supported the results of a study by
Almasi and Farahmand in Fars province.16 In
both 2007 and 2008, this cancer had a high
incidence in most Iranian provinces. In 2008, the
maximum incidence occurred in Tehran province
(6.72 per 100,000 persons), followed by Isfahan
(5.59 per 100,000 persons), East Azerbaijan, and
Khuzestan (4.48 per 100,000 persons). In the
same year (2007 and 2008), the lowest incidence
was in Ilam province with no cases reported. In
2009, the highest incidence was in Yazd (7.14
per 100,000 persons), Isfahan (5.99 per 100,000
persons), and Tehran (5.84 per 100,000 persons)
compared to Kohkiluye Boyer-Ahmad province
that had the lowest incidence. No study has been
conducted in Iran that compared the incidence rate
in different provinces and regions and with the
statistics from the Ministry of Health. In 2013,
Kuji et al. conducted a study in Portugal, which
showed that the mortality rate for cervical cancer
was higher in developing countries; more than
85% of cervical cancer occurred in developing
countries.17 multiple studies have shown that the
disease burden varies in different ethnicities and
groups within a society. A study in 2013 conducted
in China by Rijkaart et al. has confirmed the
observation.18 The incidence of cervical cancer is
increasing according to studies conducted in other
parts of the world and Iran. According to WHO
reports, 529,000 new cases of this disease and
275,000 cases of cancer-related deaths occurred
annually. The cervical cancer incidence has been
growing in recent decades.9,10,19 Studies by
Xiaoyan Liu et al.  in China in 2013 and Ferlay
in the United States in 2010 confirmed these
results.8,21-24 One reason for the growing incidence
of cervical cancer in Iran might be the shifting
pattern of cervical cancer risk factors that include
life-style changes in the population and changes
in the prevalence of risk factors that lead to real
changes in disease incidence. Another factor for
the increased incidence may be the higher rates of
diagnosis due to increased use of screening tests
like Pap smears. Pap smears are being performed
throughout Iran for at-risk populations. Another
reason for this variation may be the different
methods of data collection. Cancer registries have
been population-based since 2006. Possible
variations in diagnostic methods, and increasing
their awareness about the importance of reporting
cases, and other possible causes such as the cohort
effect or age effect may be also effective.
Conclusion
In Iran, according to the National Cancer
Registry Center statistics, cervical cancer has an
increasing trend. The incidence of this cancer is
higher in central regions compared to other areas
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of the country. Hence, assessing the etiology in
Iran, especially in the central provinces, seems
necessary. We recommend that etiologic and
pathologic studies, as well as ongoing programs
be designed and implemented to increase public
awareness. According to the results, the programs
of the above-mentioned regions for reduction of
human papillomavirus infection could possibly be
effective in fighting cancer. However,
implementing extensive screening programs and
vaccination against human papillomavirus in
teenage and young girls needs additional study to
determine its cost-effectiveness.
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